naproxen delayed release naproxen tablet delayed release
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of Naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen delayed-release tablets are indicated: For the relief of the signs and symptoms of rheumatoid arthritis For the relief of the signs and symptoms of osteoarthritis For the relief of the signs and symptoms of ankylosing spondylitis For the relief of the signs and symptoms of juvenile arthritis Naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION ).
avkare, inc.
OVAL WHITE I 1
Related Pills
Naproxen 375 MG Delayed Release Oral Tablet
AvKARE, Inc.
Naproxen 500 MG Delayed Release Oral Tablet
AvKARE, Inc.
glimepiride 1 mg
virtus pharmaceuticals
acycycloguanosine 200 MG Oral Capsule
Carlsbad Technology, Inc.
tramadol hydrochloride tablet
virtus pharmaceuticals
Diethylpropion Hydrochloride 24 HR Diethylpropion Hydrochloride 75 MG Extended Release Oral Tablet
Preferred Pharmaceuticals, Inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
HOW SUPPLIED Naproxen Delayed-release Tablets USP: 375 mg: white Enteric coated, capsule-shaped, biconvex tablets de-bossed with ‘I 1’ on one side, supplied in bottles of 100’s count (NDC 42291-629-01). Naproxen Delayed-release Tablets USP: 500 mg: white Enteric coated, capsule-shaped, biconvex tablets de-bossed with ‘I 11’ on one side, supplied in bottles of 100’s count (NDC 42291-630-01). Store at 20° to 25°C (68° to 77°F); [See USP Controlled Room Temperature]. Dispense in tight, lightÂ-resistant containers. Manufactured for: AvKARE, Inc. Pulaski, TN 38478 Mfg. Rev. 12/11 AV 10/13 (P)
More pills like OVAL I 1